Manufacturing

Manufacturing

R-Pharm’s production designed with account to all latest GMP requirements, which is unprecedented for Russia, especially for the production of aseptic injection drug formulations.

Новости

Alexey Repik Participates in All-Russian Forum IV “Future Intellectual Leaders of Russia”

Alexey Repik Participates in All-Russian Forum IV “Future Intellectual Leaders of Russia”

The All-Russian Forum “Future Intellectual Leaders of Russia” took place in Yaroslavl on November 21-24th, 2016. R-Pharm again supports the event as a general sponsor and co-organizer introducing the discipline “Health Technology”.

Nov. 23, 2016

Young Professionals of R-Pharm Perform at WorldSkills Hi-Tech National Championship

Young Professionals of R-Pharm Perform at WorldSkills Hi-Tech National Championship

Championship III in cross-industry blue-collar jobs of hi-tech section took place in Yekaterinburg from October 30th to November 3d. R-Pharm group acted as the organizer of the competence “Laboratory Chemical Analysis”.

Nov. 17, 2016

Violations Committed Upon Purchase of Avastin That Caused Blindness

news

On Wednesday, November 9th, the head of Federal Service for Surveillance and Healthcare of the Russian Federation (Roszdravnadzor) Mikhail Murashko reported that the Service had completed inspection of a batch of Avastin drug that caused blindness in 11 patients of Helmholtz clinic in Moscow.

Nov. 9, 2016

R-Pharm Group Rolls Out New Drug Arlansa (Narlaprevir) for Treatment of Chronic Viral Hepatitis C

R-Pharm Group Rolls Out New Drug Arlansa (Narlaprevir) for Treatment of Chronic Viral Hepatitis C

A new direct acting antiviral drug Arlansa (Narlaprevir) for therapy of VHC was introduced within All-Russian research and practice conference III with international engagement “Socially significant and highly infectious diseases” in Sochi on November 3d, 2016. This is the first registered pelleted domestic NS3 serine protease inhibitor administered in combination with other antiviral drugs. On the first day of the conference, November 1st, there took place a research and practice forum named “Domestic VHC protease inhibitor: from development to clinical practice” where final clinical findings for Arlansa were introduced as well as prospects of its administration as part of chronic VHC interferon-free regiment. The following persons took part in the conference: I.V. Shestakova, the chief independent infectiologist of Ministry of Healthcare of the Russian Federation; V.A. Isakov, the head of gastroenterology and hepatology department of nutrition research institute of RAS; K.V. Zhdanov, correspondent member of RAS and the chief infectiologist of Ministry of Defense of the Russian Federation; I.G. Nikitin, the head of hospital therapy department of Pirogov Russian National Research Medical University; O.O. Znoyko, Professor of infectious disease department of A.I. Evdokimov Moscow State University of Medicine and Dentistry; E.A. Strebkova, Assistant Professor and the head of department of the clinic for infectious diseases of Samara State Medical University. Summarizing the results of the forum the experts emphasized the importance of introducing accessible treatment regiments for patients with noncomplicated chronic Hepatitis C in order to prevent the development of heavy liver conditions and to decrease social and economic damage caused by the disease. Narlaprevir successfully passed extensive pre-clinical and clinical trials in Schering-Plough Research Institute (USA) and in a variety of clinical centers of Europe, USA and Russia. The drug was developed in collaboration with the Texas Liver Institute (USA), the global leading hepatology center. In 2014-2016 a large scale phase III PIONEER trial was held. It was named “Evaluation of safety and efficiency of Narlaprevir in patients with chronic VHC (genotype 1) who were not treated with pegylated interferon and Ribavirin before or whose earlier treatment with those drugs was inefficient”. The largest Russian centers specialized in the treatment of viral hepatitis took part in the studies. The research made it possible to get all the required data on the use of Narlaprevir in the Russian population of patients with prevailing VHC infection genotype 1b. Based on clinical findings R-Pharm obtained a registration certificate for Arlansa (Narlaprevir) ЛП-003622 dd 12.05.2016 issued by Ministry of Healthcare of the Russian Federation. R-Pharm continues to make investments in development of the scientific basis of the drug: it holds supportive studies on drug interactions, including antiretroviral agents, as well as studies on pharmacokinetics in patients with compensated hepatic disorders. It invests in studies of the drug efficiency and safety in interferon-free combinations with other direct acting antiviral drugs. Director General of R-Pharm group Vasily Ignatiev emphasized that over 700 mln rubles were invested in the development and clinical research of Narlaprevir (completed studies and current research). The development of the drug was supported by the Federal target program “Development of pharm and medical industry of the Russian Federation until 2020 and beyond”. In 2011 Ministry of Industry and Trade and R-Pharm concluded a state contract on foreign development transfer and production of the innovative drug in Russia. R-Pharm transfers production of the drug to its pharm complex in Yaroslavl region within this contract. Arlansa (Narlaprevir) will be available in the pharmacies of Russia already in the fourth quarter of 2016. Besides Russia, R-Pharm is planning to commercialize this medication in a number of other countries where chronic VHC genotype 1b prevails, specifically in Turkey. Contacts for Media: Anna Voronina Tel: +7-495-956-79-37 ext. 2110 Mob: 8-925-804-16-72 e-mail: voronina@rpharm.ru

Nov. 3, 2016

The foundation stone of a plant to be constructed in partnership with R-Pharm was laid in Azerbaijan

The foundation stone of a plant to be constructed in partnership with R-Pharm was laid in Azerbaijan

The foundation stone laying ceremony to mark the foundation of a hi-tech pharm complex named Hayat Pharm was held in Pirallahi industrial estate near Baku, Azerbaijan, on November 2nd, 2016. In order to carry out the project a joint venture was established by the following shareholders: R-Pharm group of companies (the Russian Federation), Vita-A LLC (Republic of Azerbaijan) and Azerbaijan Investment Company (Ministry of Economy, Republic of Azerbaijan).

Nov. 2, 2016
News Archive →